Neurological outcomes in late HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy

AIDS

Volumn 13, Issue 13, 1999, Pages 1677-1685

  Price, Richard W ^a   Yiannoutsos, Constantin T ^b   Clifford, David B ^c   Zaborski, Lawrence ^b   Tselis, Alex ^d   Sidtis, John J ^e   Cohen, Bruce ^f   Hall, Colin D ^g   Erice, Alejo ^e   Henry, Keith ^e   Glicksman, M ^k   Powderly, W G ^k   Swindells, S ^k   Rudberg, G ^k   Cooper, C ^k   Kessler, H ^k   Borucki, M ^k   Galatas, P ^k   Van der Horst, C ^k   Kapoor, C ^k   Robertson, K ^k   Robertson, W ^k   Simpson, D ^k   Dorfman, D ^k   Sinclair, B ^k   Olson, C ^k   Marder, K ^k   Crawford, M ^k   Flynn, T ^k   Wanke, C ^k   Craven, D ^k   Reid, J ^k   Holloway, R ^k   Fife, K ^k   Todd, K ^k   Marra, C M ^h   Collier, A C ^h   Cummings, D ^h   Tyler, K L ^k   Putnam, B A ^k   Hollander, H ^k   Walker, J ^k   Matozzo, I ^k   Frank, I ^k   Kumar, P ^k   Guerrero, M ^k   Kruger, S ^k   Fischl, M ^k   Scerpella, E ^k   Rodriguez, A ^k   Frame, P T ^k   Kohrs, S ^k   Lederman, M ^k   Vazquez, G ^k   Lopez, I ^k   Delapenha, R ^k   Butler, Y ^k   Saag, M ^k   Squires, K E ^k   Deloach, S ^k   McCulloch, B ^k   Cooney, E ^k   Frank, C ^k   Nealon, M J ^k   Ponticello, L ^k   Sociro, R ^k   Valentine, F ^k   Vogler, M ^k   Chirgwin, K ⁱ   Szebenyi, S ^k   Rinki, M ^k   Slamowitz, D ^k   Ogata Arakaki, D ^k   Millard, M ^k   Ellis, R ^j   Snyder, R ^j   Eyster, M E ^k   Ehmann, C ^k   Kessler, C ^k   Quinlan, C ^k   Brettler, D B ^k   Forand, P ^k   Seremetis, S ^k   Brady, M ^k   Hunkler, J ^k   Saba, H ^k   Tannenbaum, B ^k   Hoots, K ^k   Coates, T D ^k   Sosa, A ^k   South, M A ^k   Rubinstein, A ^k   Weiler Einstein, J ^k   Gill, J ^k   Timmons, P ^k   Stabler, S ^k   Giambartolomei, S ^k   Clax, P ^k   Kenton, A ^k   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k NONE

more..

Author keywords

AIDS dementia complex; Antiretroviral therapy; CD4 T lymphocytes; Central nervous system; Didanosine; Neuropsychological test; Nevirapine; Reverse transcriptase inhibitors; Viral load; Zalcitabine; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL; VIRUS LOAD;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS;

EID: 16744362308     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199909100-00011     Document Type: Article

References (44)

1. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: IL Neuropathology. Ann Neurol 1986, 19:525-535.
2. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. clinical features. Ann Neurol 1986, 19:517-524.
3. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988, 158:1079-1083.
4. Price RW. Brew B, Sidtis J, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988, 239:586 592.
5. Navia BA, Clinical and biologic features of the AIDS dementia complex. Neuroimaging Clin N Am 1997, 7:581-592.
6. Anonymous. Nomenclature and research case definitions for neurolugic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force [see comments]. Neurology 1991, 41:778-785.
7. Iross S, Price RW, Navia B, et al. Neuropsychological characterization of the AIDS dementia complex: a preliminary report. AIDS 1988, 2: 281-288.
8. Cummings JL, Benson DF. Subcortical dementia. Review of an emerging concept. Arch Neurol 1984, 41:874-879.
9. Lipton SA, Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boslon. Dementia associated with the acquired immunodeficiency syndrome [see comments]. Engl J Med 1995, 332:934-940.
10. Pricc R. Management of AIDS dementia complex and HIV-1 infection of the nervous system. AIDS 1995, 9(SupplA):S221-S236.
11. Kolson DI, Lavi E, González Scarano F. The effects of human immunodeficiency virus in the central nervous system. Adv Virus Res 1998, 50:1-47.
12. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection [see comments]. N Engl J Mod 1988, 319:889-896.
13. Schmitt FA, Bigley JW, MCKinnis R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Mod 1988, 319:1573-1578.
14. Sidtis JJ, Galsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 1993, 33:343-349.
15. Portegies P, Enting RH, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AID5 1993, 7:669-675.
16. Sidtis JJ, Dafni U, Slasor P, et al. Stable neurological function in subjects treated with 2′ 3′-dideoxyinosine. J Neurovirol 1997, 3:233-240.
17. Brouwers P, Hendricks M, Lietzau JA, et al. Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. AIDS 1997, 11:59-66.
18. Ferrando S, van Gorp W, MCElhiney M, et al. Highly active anti-retroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 1998, 12:F63-F70.
19. Moore R, Keruly J, Gallant J, Chaisson R. Decline in mortality rates and opportunistic disease with combination antiretroviral therapy. 12th World AIDS Conference. Geneva, Switzerland, 1998 [abstract 22374].
20. Brew B, Brown S, Catalan J, et al. Safely and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (Study CNAB 3001). 12th World AIDS Conference. Geneva, Switzerland, 1998 [abstract 32192].
21. Henry WK, Erice A, Tierney C, et al. A randomized, controlled double-blind clinical trial comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug and alternating drug) for the treatment of advanced AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19: 339-349.
22. Price RW, Sidtis JJ. Evaluation of the AIDS dementia complex in clinical trials. J Acquir Immune Defic Syndr 1990, 3 Suppl 2:S51-S60.
23. Sidtis JJ. Evaluation of the AIDS dementia complex in adults. [Review], Research Publications - Association for Research in Nervous & Mental Disease 1994, 72:273-287.
24. Navia BA, Dafni U, Simpson D, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998, 51:221-228.
25. Wechsler D. Wechsler adult intelligence scale-revised. New York: Psychological Corporation. 1981.
26. Reitan R, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Phoenix: Neuropsychology Press. 1985.
27. Lezak M. Neuropsychological assessment. Third edition. New York: Oxford University Press. 1995.
28. Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall. 1984.
29. Bornstein RA, Nasrallah HA, Para MF, Whitacre CC, Fass RJ. Duration of illness and neuropsychological performance in asymptomatic HIV infection. J Neuropsychiatry Clin Neurosci 1994, 6:160-164.
30. Neaton ID, Wentworth DN, Rhame F, et al. Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Stat Med 1994, 13:2107-2125.
31. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994, 44:1892-1900.
32. Sacktor N, Skolasky R, Esposito D, et al. Combination antiretroviral therapy including protease inhibitors improves psychomotor speed performance in HIV infection. Neurology 1998, 50;A248-A249.
33. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998, 47(No. RR-5).
34. Burger DM, Kraaijeveld C, Meenhorst P, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993, 7:1581-1587.
35. Enting R, Hoetelmans R, Lange J, et al. Antiretroviral drugs and the central nervous system. AIDS 1998, 12:1941-1955.
36. Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 1998, 87:306-310.
37. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993, 43:2245-2252.
38. Sacktor NC, Bacellar H, Hoover DR, et al. Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death, J Neurovirol 1996, 2:404-410.
39. Goodkin K, Wilkie FL, Concha M, et al. Subtle neuropsychological impairment and minor cognitive-motor disorder in HIV-1 infection. Neuroradiological, neurophysiological, neuroimmunological, and virological correlates. Neuroimaging Clin N Am 1997, 7:561-579.
40. Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997, 54:416-424.
41. Gail MH, Tan WY, Pee D, Goedert JJ. Survival after AIDS diagnosis in a cohort of hemophilia patients. Multicenter Hemophilia Cohort Study. J Acquit Immune Defic Syndr Hum Retrovirol 1997, 15:363-369.
42. Wilkie FL, Goodkin K, Eisdorfer C, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci 1998, 10:125-132.
43. Price R. The cellular basis of central nervous system HIV-1 infection and the AID5 dementia complex: introduction. J Neuro-AIDS 1995, 1:1-28.
44. Price RW, Staprans S. Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? [editorial comment]. Ann Neurol 1997, 42:675-678.